Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is a biopharmaceutical company with a strong focus on developing innovative treatments for various ocular diseases, including diabetic macular edema, dry eye disease, and acute optic neuritis. Despite a setback in their OCS-01 program, their promising results in the OCS-02 and OCS-05 trials, coupled with FDA breakthrough and EMA PRIME designations and a strong cash runway into 2029, make the company a strong candidate for growth and development. However, as with any clinical-stage company, there is inherent risk in the success of their trials and regulatory approvals for their products. Therefore, investors should carefully consider the potential risks and rewards before making an investment decision.

Bears say

Oculis Holding is a biopharmaceutical company with a diversified ophthalmology pipeline targeting underserved areas of ophthalmic and retinal diseases. The failure of their lead program, OCS-01, in clinical trials and the potential for future delays in development due to third-party and financing risks may hinder the company's potential for success. Additionally, competition and tariffs on imported products could impact the company's profitability and market standing.

OCS has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 9 analysts, OCS has a Strong Buy consensus rating as of Jun 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.